- Home
- GHY vs SENS Comparison
GHY vs SENS Comparison
Compare GHY & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GHY | SENS |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.3M | 496.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | GHY | SENS |
|---|---|---|
| Price | $11.27 | $8.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 131.6K | ★ 664.3K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $11.25 | $0.41 |
| 52 Week High | $13.33 | $10.15 |
Technical Indicators
Market Signals| Indicator | GHY | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 26.50 | 55.02 |
| Support Level | $11.25 | $5.13 |
| Resistance Level | $12.04 | $10.07 |
| Average True Range (ATR) | 0.09 | 0.55 |
| MACD | -0.02 | -0.18 |
| Stochastic Oscillator | 1.16 | 20.01 |
Price Performance
Historical ComparisonAbout GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.